Advertisements


Psychoanalysing NATO: Projection

Authored by Patrick Armstrong via The Strategic Culture Foundation, "NATO" can be a rather elusive concept: Libya was a NATO operation, even though Germany kept out of it. Somalia was not a NATO operation even though Germany.....»»

Category: blogSource: zerohedgeJul 4th, 2018

Patterson-UTI (PTEN) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Patterson-UTI (PTEN) closed at $16.01, marking a -1.54% move from the previous day. Patterson-UTI (PTEN) closed at $16.01 in the latest trading session, marking a -1.54% move from the prior day. This change lagged the S&P 500's daily gain of 1.47%. At the same time, the Dow lost 0.11%, and the tech-heavy Nasdaq gained 7.94%.Coming into today, shares of the provider of onshore contract drilling services had lost 0.25% in the past month. In that same time, the Oils-Energy sector gained 1.59%, while the S&P 500 gained 7.41%.Wall Street will be looking for positivity from Patterson-UTI as it approaches its next earnings report date. This is expected to be February 8, 2023. On that day, Patterson-UTI is projected to report earnings of $0.43 per share, which would represent year-over-year growth of 213.16%. Meanwhile, our latest consensus estimate is calling for revenue of $759.51 million, up 62.81% from the prior-year quarter.Investors should also note any recent changes to analyst estimates for Patterson-UTI. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection has moved 10.86% higher. Patterson-UTI is currently a Zacks Rank #1 (Strong Buy).Digging into valuation, Patterson-UTI currently has a Forward P/E ratio of 6.73. Its industry sports an average Forward P/E of 10.53, so we one might conclude that Patterson-UTI is trading at a discount comparatively.The Oil and Gas - Drilling industry is part of the Oils-Energy sector. This industry currently has a Zacks Industry Rank of 10, which puts it in the top 4% of all 250+ industries.The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Patterson-UTI Energy, Inc. (PTEN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research.....»»

Category: topSource: zacksFeb 2nd, 2023

Immunocore Holdings PLC Sponsored ADR (IMCR) Outpaces Stock Market Gains: What You Should Know

Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $63.52, moving +1.78% from the previous trading session. In the latest trading session, Immunocore Holdings PLC Sponsored ADR (IMCR) closed at $63.52, marking a +1.78% move from the previous day. This move outpaced the S&P 500's daily gain of 1.47%. At the same time, the Dow lost 0.11%, and the tech-heavy Nasdaq gained 7.94%.Prior to today's trading, shares of the company had gained 14.72% over the past month. This has outpaced the Medical sector's loss of 0.48% and the S&P 500's gain of 7.41% in that time.Wall Street will be looking for positivity from Immunocore Holdings PLC Sponsored ADR as it approaches its next earnings report date. The company is expected to report EPS of -$0.03, up 97.52% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $51.14 million, up 474.61% from the prior-year quarter.Any recent changes to analyst estimates for Immunocore Holdings PLC Sponsored ADR should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 7.11% higher. Immunocore Holdings PLC Sponsored ADR is holding a Zacks Rank of #3 (Hold) right now.The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 91, which puts it in the top 37% of all 250+ industries.The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research.....»»

Category: topSource: zacksFeb 2nd, 2023

Ardelyx (ARDX) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Ardelyx (ARDX) closed at $3.07, marking a +1.99% move from the previous day. Ardelyx (ARDX) closed the most recent trading day at $3.07, moving +1.99% from the previous trading session. This move outpaced the S&P 500's daily gain of 1.47%. At the same time, the Dow lost 0.11%, and the tech-heavy Nasdaq gained 7.94%.Heading into today, shares of the biotechnology company had gained 7.12% over the past month, outpacing the Medical sector's loss of 0.48% and lagging the S&P 500's gain of 7.41% in that time.Investors will be hoping for strength from Ardelyx as it approaches its next earnings release. In that report, analysts expect Ardelyx to post earnings of $0.01 per share. This would mark year-over-year growth of 103.23%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $27.71 million, up 2589.9% from the year-ago period.Investors should also note any recent changes to analyst estimates for Ardelyx. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Ardelyx currently has a Zacks Rank of #2 (Buy).The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 97, which puts it in the top 39% of all 250+ industries.The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ardelyx, Inc. (ARDX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research.....»»

Category: topSource: zacksFeb 2nd, 2023

Coty (COTY) to Report Q2 Earnings: What"s in the Offing?

Coty's second-quarter fiscal 2023 performance is most likely to reflect the adverse impact of inflationary pressure and supply-chain-related headwinds. Unfavorable currency rates are a concern. Coty Inc. COTY is likely to register top and bottom line declines when it reports second-quarter fiscal 2023 earnings on Feb 8. The Zacks Consensus Estimate for revenues is pegged at $1,539 million, suggesting a decrease of 3.2% from the prior-year quarter’s reported figure.The Zacks Consensus Estimate for Coty’s fiscal second-quarter bottom line has remained unchanged in the past 30 days at 15 cents per share. The projection indicates a decline of 11.8% from the year-ago quarter’s reported figure. The cosmetics company has a trailing four-quarter earnings surprise of 22.9%, on average. In the last reported quarter, the company’s bottom line was in line with the Zacks Consensus Estimate.We expect fiscal second-quarter net revenues to be down 2.5% year over year to $1,538.9 million and the bottom line to decline 22.9% to 13 cents a share.Coty Price and EPS Surprise  Coty price-eps-surprise | Coty Quote Things to ConsiderCoty has been battling persistent inflation for a while now. The global supply-chain-related challenges and rising demand for fragrances has been leading to industry-wide supply constraints for key fragrance components. The persistence of such hurdles might have hurt the company’s performance in the second quarter of fiscal 2023.Coty’s international presence keeps it exposed to the risk of adverse currency fluctuations. In its last earnings call, management highlighted that it expects unfavorable currency rates to impact fiscal second-quarter sales by 7-9%. In addition, the company expects the net impact of its Russia exit to have hurt quarterly sales by approximately 3%.That said, management expects first-half core business LFL revenue growth trends to be consistent with the annual growth target of 6-8%, with demand remaining robust in fiscal second-quarter. The company also expects modest gross margin expansion in the quarter amid a rising inflationary environment.What the Zacks Model UnveilsOur proven model predicts an earnings beat for Coty this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Coty carries a Zacks Rank #3 and has an Earnings ESP of +0.92%.Some Other Stocks With Favorable CombinationsHere are three other companies you may want to consider, as our model shows they these have the right combination of elements to post an earnings beat:Performance Food Group Company PFGC currently has an Earnings ESP of +0.39% and a Zacks Rank #3. The company is expected to register bottom line growth when it reports second-quarter fiscal 2023 results. The Zacks Consensus Estimate for quarterly earnings per share of 76 cents suggests an increase from the 57 cents reported in the year-ago quarter. You can see the complete list of today’s Zacks #1 Rank stocks here.Performance Food Group Company's top line is anticipated to rise year over year. The consensus mark for revenues is pegged at $13.91 billion, indicating an increase of 8.4% from the figure reported in the year-ago quarter. PFGC has a trailing four-quarter earnings surprise of 15.2%, on average.Freshpet, Inc. FRPT is likely to register top and bottom line growth when it reports fourth-quarter 2022 results. FRPT has an Earnings ESP of +2.04% and a Zacks Rank #3. The Zacks Consensus Estimate for Freshpet’s bottom line has remained unchanged at a loss of 8 cents in the past 30 days, indicating 61.9% growth from the year-ago period’s reported figure.FRPT has a trailing four-quarter negative earnings surprise of roughly 88%, on average. The consensus mark for Freshpet’s top line is pegged at $151.1 million, calling for growth of 30.4% from the prior-year quarter’s reported figure.Kellogg Company K currently has an Earnings ESP of +4.12% and a Zacks Rank of 3. K is expected to register a top line improvement when it reports fourth-quarter 2022 numbers.The Zacks Consensus Estimate for Kellogg's quarterly revenues is pegged at $3.7 billion, calling for growth of almost 7% from the prior-year quarter’s reported figure. The Zacks Consensus Estimate for the quarterly EPS of 84 cents indicates growth of 1.2% compared with the figure reported in the year-ago fiscal quarter. K has a trailing four-quarter earnings surprise of 10.6%, on average.Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Freshpet, Inc. (FRPT): Free Stock Analysis Report Kellogg Company (K): Free Stock Analysis Report Coty (COTY): Free Stock Analysis Report Performance Food Group Company (PFGC): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research.....»»

Category: topSource: zacksFeb 2nd, 2023

Factors Setting the Tone for Royal Caribbean (RCL) Q4 Earnings

Royal Caribbean's (RCL) fourth-quarter performance is likely to have benefited from improving booking volumes, digital initiatives and fleet expansion efforts. Royal Caribbean Cruises Ltd. RCL is scheduled to release fourth-quarter 2022 results on Feb 7, 2023. In the previous quarter, RCL delivered an earnings surprise of 13%.The Trend in Estimate RevisionThe Zacks Consensus Estimate for Royal Caribbean’s fourth-quarter bottom line is pegged at a loss of $1.37 per share. In the prior-year quarter, RCL reported a loss per share of $4.78.For revenues, the consensus mark is pegged at $2,605 million. The projection suggests an increase of 165.2% from the year-ago quarter’s reported figure.Royal Caribbean Cruises Ltd. Price and EPS Surprise  Royal Caribbean Cruises Ltd. price-eps-surprise | Royal Caribbean Cruises Ltd. Quote Let’s take a look at how things have shaped up for the quarter to be reported.Factors at PlayRoyal Caribbean’s fourth-quarter performance is likely to have benefited from is likely to benefit from improving booking volumes, digital initiatives and fleet-expansion efforts. During the previous quarter’s earnings call, RCL reported accelerating demand for sailings in 2023. It stated that booking volumes for 2023 doubled during the third quarter compared with the second quarter of 2022. The company noted better than expected load factors, owing to a rise in close-in bookings. Also, it reported early consumer engagement, with about 60% purchasing onboard experiences before the sailings.Given that the majority of its destinations and markets (outside China) resumed operations, the momentum is likely to have continued in the fourth quarter. Emphasis on new innovative ships and enhanced onboard experiences are likely to have aided the company’s performance in the to-be-reported quarter. For the fourth quarter of 2022, the company anticipates total revenues to be nearly $2.6 billion.However, supply-chain constraints, elevated expenses (including fuel and food), uncertainty revolving around pandemic-induced cancellations and changing protocols might have affected RCL’s performance in the fourth quarter. For the fourth quarter of 2022, the company expects depreciation and amortization expenses in the range of $355-$365 million. Net interest expenses for the fourth quarter are expected to be $355-365 million. The company expects adjusted loss per share in the fourth quarter to be in the range of $1.30-$1.50.What the Zacks Model UnveilsOur proven model predicts an earnings beat for Royal Caribbean this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.Earnings ESP: Royal Caribbean has an Earnings ESP of +0.97%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Zacks Rank: Royal Caribbean has a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.Other Stocks Poised to Beat on EarningsHere are some other stocks worth considering from the Zacks Consumer Discretionary sector, as our model shows that these have the right combination of elements to beat on earnings this season.Red Rock Resorts, Inc. RRR has an Earnings ESP of +17.33% and a Zacks Rank #3.Shares of Red Rock Resorts have gained 3.6% in the past year. RRR’s earnings surpassed the consensus mark in all the trailing four quarters, the average surprise being 66.7%.Roku, Inc. ROKU has an Earnings ESP of +1.97% and a Zacks Rank #3.Shares of Roku have declined 61.8% in the past year. ROKU’s earnings surpassed the estimates twice in the trailing four quarters and missed twice, the average surprise being 50.6%.Planet Fitness, Inc. PLNT has an Earnings ESP of +2.53% and a Zacks Rank #3.Shares of Planet Fitness have declined 5.2% in the past year. PLNT’s earnings surpassed the consensus mark in all the trailing four quarters, the average surprise being 6.6%.Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Royal Caribbean Cruises Ltd. (RCL): Free Stock Analysis Report Planet Fitness, Inc. (PLNT): Free Stock Analysis Report Red Rock Resorts, Inc. (RRR): Free Stock Analysis Report Roku, Inc. (ROKU): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research.....»»

Category: topSource: zacksFeb 2nd, 2023

BD (BDX) Q1 Earnings and Revenues Beat Estimates, Margins Down

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter. Becton, Dickinson and Company BDX, popularly known as BD, delivered adjusted earnings per share (EPS) of $2.98 in the first quarter of fiscal 2023, down 5.9% year over year. The figure, however, surpassed the Zacks Consensus Estimate by 11.6%.The adjustments include expenses related to purchase accounting adjustments and integration costs, among others.We had projected the fiscal first-quarter adjusted EPS to be $2.64.GAAP EPS for the quarter was $1.70, reflecting a decline of 10.5% from the year-earlier figure.Revenues in DetailBD registered revenues of $4.59 billion in the fiscal first quarter, down 2.8% year over year. However, the figure surpassed the Zacks Consensus Estimate by 0.9%.The fiscal first-quarter revenue compares to our estimate of $4.51 billion.At constant exchange rate (CER), revenues climbed 1.7%.The top-line improvement primarily resulted from strength in BD Medical and BD Interventional segments. However, the overall top-line improvement was partially offset by a fall in worldwide COVID-19-only diagnostic testing revenues.Base revenues were $4.55 billion in the fiscal first quarter, up 0.4% year over year on a reported basis and 5.2% at CER.Base organic revenue growth for the fiscal first quarter was down 1.7% on a reported basis but up 3% at CER.Segment DetailsBD’s operations consist of three worldwide business segments — BD Medical, BD Life Sciences and BD Interventional.For the quarter under review, BD Medical reported worldwide revenues of $2.15 billion, up 1.6% from the year-ago quarter on a reported basis and 6.1% at CER. Per management, this upside can be attributed to strong performances by the Medication Management Solutions and Pharmaceutical Systems business units.This compares to our projection of fiscal first-quarter segmental revenues of $2.11 billion.Worldwide revenues in the BD Life Sciences segment totaled $1.30 billion, down 12.2% year over year on a reported basis and down 7.3% at CER. The decline resulted primarily from the Integrated Diagnostic Solutions (IDS) unit’s fall in COVID-only diagnostic testing revenues. However, this was partially offset by the IDS unit’s strong growth in the base business (driven by strong demand for BD’s respiratory testing portfolio, which was partly aided by timing of dealer orders, strong BD Kiestra lab automation installations and leveraging its higher BD MAX installed base for molecular In Vitro Diagnostic assay growth) and strength in the Biosciences unit.The fiscal first-quarter revenue compares to our estimate of $1.33 billion.BD Interventional segment generated worldwide revenues of $1.13 billion, up 1.3% from the year-ago quarter on a reported basis and 5.6% at CER. This was owing to strength in the Peripheral Intervention business unit.The fiscal first-quarter revenue compares to our estimate of $1.07 billion.Geographic ResultsIn the first quarter of fiscal 2023, revenues in the United States improved 0.9% to $2.73 billion.The fiscal first-quarter revenue compares to our estimate of $2.56 billion.International revenues grossed $1.86 billion, down 7.9% from the year-ago quarter on a reported basis but up 2.7% at CER.The fiscal first-quarter revenue compares to our estimate of $1.95 million.Becton, Dickinson and Company Price, Consensus and EPS Surprise  Becton, Dickinson and Company price-consensus-eps-surprise-chart | Becton, Dickinson and Company Quote Margin AnalysisIn the quarter under review, BD’s gross profit fell 3.9% to $2.13 billion. Gross margin contracted 54 basis points (bps) to 46.5%.We had projected 44.9% of gross margin for the fiscal first quarter.Selling and administrative expenses rose 0.2% to $1.19 billion. Research and development expenses declined 0.3% year over year to $313 million. Adjusted operating expenses of $1.50 billion increased 0.1% year over year.Adjusted operating profit totaled $633 million, reflecting a 12.2% decline from the prior-year quarter. The adjusted operating margin in the fiscal first quarter contracted 148 bps to 13.8%.Financial PositionBD exited the first quarter of fiscal 2023 with cash and cash equivalents, and short-term investments of $612 million compared with $1.01 billion at the end of fiscal 2022. Total debt (including current debt obligations) at the end of first-quarter fiscal 2023 was $16.46 billion compared with $16.07 billion at the end of fiscal 2022.Net cash flow from continuing operating activities at the end of first-quarter fiscal 2023 was $399 million compared with $530 million a year ago.Meanwhile, BD has a consistent dividend-paying history, with its five-year annualized dividend growth being 3.97%.Fiscal 2023 GuidanceBD has revised its financial outlook for fiscal 2023.BD now projects its full fiscal year revenues to be in the range of $19.1 billion-$19.3 billion, up from the earlier-provided projections of $18.6 billion-$18.8 billion. The Zacks Consensus Estimate for revenues is pegged at $18.88 billion.The revenue projections for fiscal 2023 now include base-business revenue growth at CER of 5.75-6.75%, up from the earlier expectations of an uptick of 5.25-6.25%.The outlook now estimates around $50 million-$100 million in COVID-19-only diagnostic testing revenues, down from the earlier projections of $125 million-$175 million.For the full fiscal year, adjusted EPS is now anticipated to be $12.07-$12.32, up from the earlier estimates of $11.85-$12.10. The Zacks Consensus Estimate for the same is pegged at $11.94.Our TakeBD exited the first quarter of fiscal 2023 with better-than-expected results. An improvement in the overall base revenues and robust performances by the majority of its segments and in the United States are impressive. Strength in BD’s segment’s business units during the reported quarter was also promising.BD’s recent agreement with Biocorp and a co-exclusive commercial agreement with Magnolia Medical Technologies, Inc. look promising. BD’s recent launch of a new, robotic track system for the BD Kiestra microbiology laboratory solution — 3rd Generation BD Kiestra Total Lab Automation System — is encouraging. BD and CerTest Biotec’s receipt of the FDA’s Emergency Use Authorization for VIASURE Monkeypox Virus Real Time PCR (polymerase chain reaction) Reagents for BD MAX System, which is now available for BD MAX System users, also raises our optimism.However, the year-over-year decline in reported revenues is disappointing. The fall in BD Life Sciences and international revenues is worrying. Lower COVID-only testing revenues in the quarter and BD’s expectations of its continued fall during fiscal 2023 are discouraging from a business perspective. The contraction of both margins also does not bode well.Zacks Rank and Key PicksBD currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the broader medical space that have announced quarterly results are Neogen Corporation NEOG, McKesson Corporation MCK and Hologic, Inc. HOLX.Neogen, carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2023 adjusted EPS of 15 cents, beating the Zacks Consensus Estimate of a loss of 8 cents per share. Revenues of $230 million outpaced the consensus mark by 0.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Neogen has a return on equity of 5.6% against the industry’s negative return. NEOG’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average being 70.1%.McKesson, having a Zacks Rank #2, reported third-quarter fiscal 2023 adjusted EPS of $6.90, which beat the Zacks Consensus Estimate by 8.8%. Revenues of $70.49 billion outpaced the consensus mark by 0.02%.McKesson has a long-term estimated growth rate of 10.1%. MCK’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average being 3.4%.Hologic reported first-quarter fiscal 2023 adjusted earnings of $1.07 per share, beating the Zacks Consensus Estimate by 18.9%. Revenues of $1.07 billion surpassed the Zacks Consensus Estimate by 9.5%. It currently sports a Zacks Rank #1.Hologic has a long-term estimated growth rate of 15.2%. HOLX’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 30.6%. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Becton, Dickinson and Company (BDX): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report Neogen Corporation (NEOG): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research.....»»

Category: topSource: zacksFeb 2nd, 2023

Accuray (ARAY) Q2 Earnings and Revenues Top Estimates

Despite solid product demand, Accuray (ARAY) reports an overall soft fiscal Q2 performance. Accuray Incorporated ARAY reported a loss of 2 cents per share for the second quarter of fiscal 2023 against the breakeven earnings per share (EPS) in the year-ago period. However, the loss per share was narrower than the Zacks Consensus Estimate of a loss of 3 cents per share.We had projected the loss per share to be 2 cents, which matched the company-reported result.Revenues in DetailAccuray registered revenues of $114.8 million in the second quarter of fiscal 2023, down 1.3% year over year. The figure topped the Zacks Consensus Estimate by 7.9%.The fiscal second-quarter revenue compares to our estimate of $108.5 million.The overall top-line growth was mainly dampened by supply-chain constraints and foreign exchange headwinds.At constant exchange rate (CER), net revenues were $120.9 million, representing a 4% increase from the prior-year period.Segmental DetailsAccuray derives revenues from two sources — Products and Services.In the fiscal second quarter, Product revenues improved 4.2% from the year-ago quarter to $63.3 million. This figure compares to our Product revenues’ fiscal second-quarter projection of $55.9 million.At CER, Product revenues improved 8%.Services revenues fell 7.3% from the year-ago quarter to $51.5 million. This figure compares to our Services revenues’ fiscal second-quarter projection of $52.6 million.At CER, Services revenues were flat.Gross product orders totaled $79 million, down 7.4% year over year. This figure compares to our gross orders’ fiscal second-quarter projection of $88.4 million.On a sequential basis, gross product orders increased 13.2%.Accuray Incorporated Price, Consensus and EPS Surprise  Accuray Incorporated price-consensus-eps-surprise-chart | Accuray Incorporated Quote Margin TrendIn the quarter under review, Accuray’s gross profit rose 0.8% to $42.9 million. Gross margin expanded 78 basis points (bps) to 37.4%.We had projected 36.3% of gross margin for the fiscal second quarter.Selling and marketing expenses rose 2.7% to $13.6 million. Research and development expenses fell 0.4% year over year to $14.6 million, while general and administrative expenses went up 12.3% year over year to $12 million. Total operating expenses of $40.3 million increased 4.2% year over year.Operating profit totaled $2.7 million in the fiscal second quarter, which declined 32.1% from the prior-year quarter. Operating margin in the fiscal second quarter contracted 107 bps to 2.4%.Financial PositionAccuray exited the second quarter of fiscal 2023 with cash and cash equivalents of $67.7 million compared with $81 million at the end of the fiscal first quarter.Total debt (including short-term debt) at the end of the fiscal second quarter was $179.8 million compared with $176.3 million at the end of the fiscal first quarter.FY23 GuidanceAccuray has reiterated its outlook for fiscal 2023 based on current expectations.The company continues to expect its fiscal year revenues to be $447 million-$455 million, reflecting year-over-year growth at the midpoint of the range of 5%. The Zacks Consensus Estimate for the same is pegged at $448.7 million.Our TakeAccuray ended the second quarter of fiscal 2023 with better-than-expected results. Robust Product revenues and geographical performances are impressive. Continued strong demand for Accuray’s ClearRT Helical kVCT Imaging for the Radixact System, Synchrony Technology and VOLO Ultra enhancement looks promising. During the reported quarter, the company received 34 new system orders globally, with notable strength in the America's region with solid year-over-year growth. In China, Accuray made impressive progress with respect to its CyberKnife and Radixact Systems, which also buoy our optimism.During the fiscal second quarter, Accuray advanced key strategic partnerships, including with C-RAD, introducing the VitalHold breast package. This is expected to allow Accuray to offer the most comprehensive breast package in the market. This also looks encouraging for the stock. Gross margin expansion bodes well for the stock.However, dismal overall top-line and bottom-line performances and lower Services revenues are disappointing. The decline in gross orders is also worrying. The operating margin contraction also does not bode well. The current global supply-chain shortages, forex woes and inflationary pressure are other challenges the company is navigating through, which is another concern.Zacks Rank and Key PicksAccuray currently carries a Zacks Rank #3 (Hold).Some better-ranked stocks in the broader medical space that have announced quarterly results are Neogen Corporation NEOG, McKesson Corporation MCK and Hologic, Inc. HOLX.Neogen, carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2023 adjusted EPS of 15 cents, beating the Zacks Consensus Estimate of a loss of 8 cents per share. Revenues of $230 million outpaced the consensus mark by 0.9%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.Neogen has a return on equity of 5.6% against the industry’s negative return. NEOG’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average being 70.1%.McKesson, having a Zacks Rank #2, reported third-quarter fiscal 2023 adjusted EPS of $6.90, which beat the Zacks Consensus Estimate by 8.8%. Revenues of $70.49 billion outpaced the consensus mark by 0.02%.McKesson has a long-term estimated growth rate of 10.1%. MCK’s earnings surpassed estimates in two of the trailing four quarters and missed the same in the other two, the average being 3.4%.Hologic reported first-quarter fiscal 2023 adjusted earnings of $1.07 per share, beating the Zacks Consensus Estimate by 18.9%. Revenues of $1.07 billion surpassed the Zacks Consensus Estimate by 9.5%. It currently sports a Zacks Rank #1.Hologic has a long-term estimated growth rate of 15.2%. HOLX’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 30.6%. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Accuray Incorporated (ARAY): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report Hologic, Inc. (HOLX): Free Stock Analysis Report Neogen Corporation (NEOG): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research.....»»

Category: topSource: zacksFeb 2nd, 2023

Pilgrim"s Pride (PPC) Set to Report Q4 Earnings: Things to Note

Pilgrim's Pride's (PPC) fourth-quarter performance is likely to have witnessed an escalated cost of sales. Pilgrim's Pride Corporation PPC is likely to register a decline in the bottom line when it reports fourth-quarter 2022 earnings on Feb 8.The Zacks Consensus Estimate for the fourth-quarter bottom line has remained unchanged in the past 30 days at breakeven. The projection indicates a significant decline from the year-ago quarter’s reported figure of 56 cents.Pilgrim's Pride has a trailing four-quarter earnings surprise of 46.1%, on average. This chicken and pork product company reported an earnings surprise of 25.3% in the last reported quarter.Pilgrim's Pride Corporation Price, Consensus and EPS Surprise Pilgrim's Pride Corporation price-consensus-eps-surprise-chart | Pilgrim's Pride Corporation QuoteFactors to ConsiderPilgrim's Pride has been grappling with an increased cost of sales for a while. In the third quarter of 2022, Pilgrim's Pride’s cost of sales increased to $3,972 million from the $3,455.7 million reported in the year-ago quarter. The persistence of this trend is a concern for the company.In the third quarter of 2022, PPC’s Mexico business saw softness in overall sales and profitability due to seasonality and weakened market conditions. Its Mexico business was hurt by major inflation and slowing demand. Further, issues with mortality in live operations led to the downside. Any continuation of these downsides might have hurt the company’s performance in the quarter under review.That being said, the company’s business investments to accelerate organic growth, mainly with key customers, bode well.What the Zacks Model UnveilsOur proven model doesn’t conclusively predict an earnings beat for Pilgrim's Pride this time. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat, which is not the case here.Pilgrim's Pride has a Zacks Rank #5 (Strong Sell) and an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Stocks With the Favorable CombinationHere are three companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat:Performance Food Group Company PFGC has an Earnings ESP of +0.39% and a Zacks Rank #3. The Zacks Consensus Estimate for its fourth-quarter 2022 earnings is pegged at 76 cents, calling for 33.3% growth from the year-ago period figure. PFGC has a trailing four-quarter earnings surprise of 15.2%, on average. You can see the complete list of today’s Zacks #1 Rank stocks here.The consensus mark for Performance Food’s top line is pegged at $13.9 billion, suggesting growth of 8.4% from the prior-year quarter’s reported figure.Freshpet, Inc. FRPT is likely to register top and bottom-line growth when it reports fourth-quarter 2022 results. FRPT has an Earnings ESP of +2.04% and a Zacks Rank #3. The Zacks Consensus Estimate for Freshpet’s bottom line has remained unchanged at a loss of 8 cents in the past 30 days, indicating 61.9% growth from the year-ago period reported figure.FRPT has a trailing four-quarter negative earnings surprise of roughly 88%, on average. The consensus mark for Freshpet’s top line is pegged at $151.1 million, calling for growth of 30.4% from the prior-year quarter’s reported figure.Kellogg Company K currently has an Earnings ESP of +4.12% and a Zacks Rank of 3. K is expected to register a top-line improvement when it reports fourth-quarter 2022 numbers.The Zacks Consensus Estimate for Kellogg's quarterly revenues is pegged at $3.7 billion, calling for growth of nearly 7% from the prior-year quarter’s reported figure. The Zacks Consensus Estimate for the quarterly EPS of 84 cents suggests a 1.2% increase from the figure reported in the year-ago fiscal quarter. K has a trailing four-quarter earnings surprise of 10.6%, on average.Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Freshpet, Inc. (FRPT): Free Stock Analysis Report Kellogg Company (K): Free Stock Analysis Report Pilgrim's Pride Corporation (PPC): Free Stock Analysis Report Performance Food Group Company (PFGC): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research.....»»

Category: topSource: zacksFeb 2nd, 2023

Canadian Natural Resources Limited (CNQ) is Attracting Investor Attention: Here is What You Should Know

Canadian Natural Resources (CNQ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. Canadian Natural Resources (CNQ) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this oil and natural gas company have returned +13.2% over the past month versus the Zacks S&P 500 composite's +7.4% change. The Zacks Oil and Gas - Exploration and Production - Canadian industry, to which Canadian Natural Resources belongs, has gained 4.2% over this period. Now the key question is: Where could the stock be headed in the near term?While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For the current quarter, Canadian Natural Resources is expected to post earnings of $1.61 per share, indicating a change of -8.5% from the year-ago quarter. The Zacks Consensus Estimate remained unchanged over the last 30 days.For the current fiscal year, the consensus earnings estimate of $8.37 points to a change of +67.7% from the prior year. Over the last 30 days, this estimate has changed -16.1%.For the next fiscal year, the consensus earnings estimate of $6.46 indicates a change of -22.7% from what Canadian Natural Resources is expected to report a year ago. Over the past month, the estimate has changed -16.1%.With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Canadian Natural Resources.The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:12 Month EPSProjected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.In the case of Canadian Natural Resources, the consensus sales estimate of $7.04 billion for the current quarter points to a year-over-year change of -4.3%. The $31.41 billion and $26.19 billion estimates for the current and next fiscal years indicate changes of +30.9% and -16.6%, respectively.Last Reported Results and Surprise HistoryCanadian Natural Resources reported revenues of $8.02 billion in the last reported quarter, representing a year-over-year change of +30.9%. EPS of $2.37 for the same period compares with $1.41 a year ago.Compared to the Zacks Consensus Estimate of $7.98 billion, the reported revenues represent a surprise of +0.5%. The EPS surprise was +13.4%.The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.Canadian Natural Resources is graded B on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Canadian Natural Resources. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Canadian Natural Resources Limited (CNQ): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research.....»»

Category: topSource: zacksFeb 2nd, 2023

Is Trending Stock Generac Holdings Inc. (GNRC) a Buy Now?

Generac Holdings (GNRC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. Generac Holdings (GNRC) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this generator maker have returned +24.2% over the past month versus the Zacks S&P 500 composite's +7.4% change. The Zacks Electronics - Power Generation industry, to which Generac Holdings belongs, has gained 19.8% over this period. Now the key question is: Where could the stock be headed in the near term?Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.Revisions to Earnings EstimatesRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.Generac Holdings is expected to post earnings of $1.72 per share for the current quarter, representing a year-over-year change of -31.5%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.For the current fiscal year, the consensus earnings estimate of $8.50 points to a change of -11.7% from the prior year. Over the last 30 days, this estimate has changed -0.9%.For the next fiscal year, the consensus earnings estimate of $7.29 indicates a change of -14.3% from what Generac Holdings is expected to report a year ago. Over the past month, the estimate has remained unchanged.Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, Generac Holdings is rated Zacks Rank #5 (Strong Sell).The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:12 Month EPSProjected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.For Generac Holdings, the consensus sales estimate for the current quarter of $1.07 billion indicates a year-over-year change of +0.3%. For the current and next fiscal years, $4.59 billion and $4.26 billion estimates indicate +22.7% and -7.1% changes, respectively.Last Reported Results and Surprise HistoryGenerac Holdings reported revenues of $1.09 billion in the last reported quarter, representing a year-over-year change of +15.4%. EPS of $1.75 for the same period compares with $2.35 a year ago.Compared to the Zacks Consensus Estimate of $1.09 billion, the reported revenues represent a surprise of -0.05%. The EPS surprise was +8.02%.The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates three times over this period.ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.The Zacks Value Style Score (part of the Zacks Style Scores system), which pays close attention to both traditional and unconventional valuation metrics to grade stocks from A to F (an An is better than a B; a B is better than a C; and so on), is pretty helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.Generac Holdings is graded D on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Generac Holdings. However, its Zacks Rank #5 does suggest that it may underperform the broader market in the near term. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Generac Holdings Inc. (GNRC): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research.....»»

Category: topSource: zacksFeb 2nd, 2023

DHT Holdings, Inc. (DHT) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to DHT Holdings (DHT). This makes it worthwhile to examine what the stock has in store. DHT Holdings (DHT) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this independent oil tanker company have returned +4.2%, compared to the Zacks S&P 500 composite's +7.4% change. During this period, the Zacks Transportation - Shipping industry, which DHT Holdings falls in, has gained 5.8%. The key question now is: What could be the stock's future direction?While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.For the current quarter, DHT Holdings is expected to post earnings of $0.34 per share, indicating a change of +780% from the year-ago quarter. The Zacks Consensus Estimate has changed +118.8% over the last 30 days.The consensus earnings estimate of $0.21 for the current fiscal year indicates a year-over-year change of +191.3%. This estimate has changed +13.3% over the last 30 days.For the next fiscal year, the consensus earnings estimate of $1.33 indicates a change of +533.3% from what DHT Holdings is expected to report a year ago. Over the past month, the estimate has changed +13.7%.With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #1 (Strong Buy) for DHT Holdings.The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:12 Month EPSRevenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.For DHT Holdings, the consensus sales estimate for the current quarter of $120.7 million indicates a year-over-year change of +145.3%. For the current and next fiscal years, $274.43 million and $417.86 million estimates indicate +34.9% and +52.3% changes, respectively.Last Reported Results and Surprise HistoryDHT Holdings reported revenues of $55.35 million in the last reported quarter, representing a year-over-year change of +47%. EPS of $0.03 for the same period compares with -$0.15 a year ago.Compared to the Zacks Consensus Estimate of $60.89 million, the reported revenues represent a surprise of -9.11%. The EPS surprise was -25%.Over the last four quarters, DHT Holdings surpassed consensus EPS estimates two times. The company topped consensus revenue estimates just once over this period.ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.DHT Holdings is graded F on this front, indicating that it is trading at a premium to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about DHT Holdings. However, its Zacks Rank #1 does suggest that it may outperform the broader market in the near term. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DHT Holdings, Inc. (DHT): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research.....»»

Category: topSource: zacksFeb 2nd, 2023

CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know

CVS Health (CVS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. CVS Health (CVS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this drugstore chain and pharmacy benefits manager have returned -4.9% over the past month versus the Zacks S&P 500 composite's +7.4% change. The Zacks Retail - Pharmacies and Drug Stores industry, to which CVS Health belongs, has lost 4.2% over this period. Now the key question is: Where could the stock be headed in the near term?While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For the current quarter, CVS Health is expected to post earnings of $1.92 per share, indicating a change of -3% from the year-ago quarter. The Zacks Consensus Estimate has changed +0.3% over the last 30 days.For the current fiscal year, the consensus earnings estimate of $8.63 points to a change of +2.7% from the prior year. Over the last 30 days, this estimate has remained unchanged.For the next fiscal year, the consensus earnings estimate of $8.84 indicates a change of +2.4% from what CVS Health is expected to report a year ago. Over the past month, the estimate has remained unchanged.With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for CVS Health.The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:12 Month EPSProjected Revenue GrowthWhile earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a company to increase its earnings for an extended period without increasing its revenues. So, it's important to know a company's potential revenue growth.In the case of CVS Health, the consensus sales estimate of $74.97 billion for the current quarter points to a year-over-year change of -2.1%. The $313.52 billion and $322.04 billion estimates for the current and next fiscal years indicate changes of +7.3% and +2.7%, respectively.Last Reported Results and Surprise HistoryCVS Health reported revenues of $81.16 billion in the last reported quarter, representing a year-over-year change of +10%. EPS of $2.09 for the same period compares with $1.97 a year ago.Compared to the Zacks Consensus Estimate of $76.53 billion, the reported revenues represent a surprise of +6.05%. The EPS surprise was +5.03%.The company beat consensus EPS estimates in each of the trailing four quarters. The company topped consensus revenue estimates each time over this period.ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.CVS Health is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.ConclusionThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about CVS Health. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CVS Health Corporation (CVS): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research.....»»

Category: topSource: zacksFeb 2nd, 2023

Investors Heavily Search Southwest Airlines Co. (LUV): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Southwest (LUV). This makes it worthwhile to examine what the stock has in store. Southwest Airlines (LUV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this airline have returned +6%, compared to the Zacks S&P 500 composite's +7.4% change. During this period, the Zacks Transportation - Airline industry, which Southwest falls in, has gained 17.5%. The key question now is: What could be the stock's future direction?While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.Earnings Estimate RevisionsHere at Zacks, we prioritize appraising the change in the projection of a company's future earnings over anything else. That's because we believe the present value of its future stream of earnings is what determines the fair value for its stock.Our analysis is essentially based on how sell-side analysts covering the stock are revising their earnings estimates to take the latest business trends into account. When earnings estimates for a company go up, the fair value for its stock goes up as well. And when a stock's fair value is higher than its current market price, investors tend to buy the stock, resulting in its price moving upward. Because of this, empirical studies indicate a strong correlation between trends in earnings estimate revisions and short-term stock price movements.For the current quarter, Southwest is expected to post earnings of $0.03 per share, indicating a change of +109.4% from the year-ago quarter. The Zacks Consensus Estimate has changed -90% over the last 30 days.The consensus earnings estimate of $2.81 for the current fiscal year indicates a year-over-year change of +142.2%. This estimate has changed -13.3% over the last 30 days.For the next fiscal year, the consensus earnings estimate of $3.98 indicates a change of +41.8% from what Southwest is expected to report a year ago. Over the past month, the estimate has changed -2.1%.With an impressive externally audited track record, our proprietary stock rating tool -- the Zacks Rank -- is a more conclusive indicator of a stock's near-term price performance, as it effectively harnesses the power of earnings estimate revisions. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for Southwest.The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:12 Month EPSRevenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.For Southwest, the consensus sales estimate for the current quarter of $5.77 billion indicates a year-over-year change of +22.9%. For the current and next fiscal years, $27.19 billion and $29.04 billion estimates indicate +14.2% and +6.8% changes, respectively.Last Reported Results and Surprise HistorySouthwest reported revenues of $6.17 billion in the last reported quarter, representing a year-over-year change of +22.2%. EPS of -$0.38 for the same period compares with $0.14 a year ago.Compared to the Zacks Consensus Estimate of $6.17 billion, the reported revenues represent a surprise of +0.11%. The EPS surprise was -1166.67%.Over the last four quarters, Southwest surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.While comparing the current values of a company's valuation multiples, such as price-to-earnings (P/E), price-to-sales (P/S) and price-to-cash flow (P/CF), with its own historical values helps determine whether its stock is fairly valued, overvalued, or undervalued, comparing the company relative to its peers on these parameters gives a good sense of the reasonability of the stock's price.As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.Southwest is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Southwest. However, its Zacks Rank #3 does suggest that it may perform in line with the broader market in the near term. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Southwest Airlines Co. (LUV): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research.....»»

Category: topSource: zacksFeb 2nd, 2023

Investors Heavily Search DecisionPoint Systems Inc. (DPSI): Here is What You Need to Know

DecisionPoint Systems Inc. (DPSI) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. DecisionPoint Systems Inc. (DPSI) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this company have returned +5%, compared to the Zacks S&P 500 composite's +7.4% change. During this period, the Zacks Computer - Software industry, which DecisionPoint Systems Inc. falls in, has gained 9%. The key question now is: What could be the stock's future direction?While media releases or rumors about a substantial change in a company's business prospects usually make its stock 'trending' and lead to an immediate price change, there are always some fundamental facts that eventually dominate the buy-and-hold decision-making.Earnings Estimate RevisionsRather than focusing on anything else, we at Zacks prioritize evaluating the change in a company's earnings projection. This is because we believe the fair value for its stock is determined by the present value of its future stream of earnings.We essentially look at how sell-side analysts covering the stock are revising their earnings estimates to reflect the impact of the latest business trends. And if earnings estimates go up for a company, the fair value for its stock goes up. A higher fair value than the current market price drives investors' interest in buying the stock, leading to its price moving higher. This is why empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.DecisionPoint Systems Inc. is expected to post earnings of $0.01 per share for the current quarter, representing a year-over-year change of +110%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.The consensus earnings estimate of $0.36 for the current fiscal year indicates a year-over-year change of +500%. This estimate has remained unchanged over the last 30 days.For the next fiscal year, the consensus earnings estimate of $0.43 indicates a change of +19.4% from what DecisionPoint Systems Inc. is expected to report a year ago. Over the past month, the estimate has remained unchanged.Having a strong externally audited track record, our proprietary stock rating tool, the Zacks Rank, offers a more conclusive picture of a stock's price direction in the near term, since it effectively harnesses the power of earnings estimate revisions. Due to the size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, DecisionPoint Systems Inc. is rated Zacks Rank #2 (Buy).The chart below shows the evolution of the company's forward 12-month consensus EPS estimate:12 Month EPSRevenue Growth ForecastEven though a company's earnings growth is arguably the best indicator of its financial health, nothing much happens if it cannot raise its revenues. It's almost impossible for a company to grow its earnings without growing its revenue for long periods. Therefore, knowing a company's potential revenue growth is crucial.In the case of DecisionPoint Systems Inc. the consensus sales estimate of $17.6 million for the current quarter points to a year-over-year change of +6.8%. The $90.54 million and $96.17 million estimates for the current and next fiscal years indicate changes of +37.3% and +6.2%, respectively.Last Reported Results and Surprise HistoryDecisionPoint Systems Inc. reported revenues of $25.71 million in the last reported quarter, representing a year-over-year change of +41.1%. EPS of $0.16 for the same period compares with $0.08 a year ago.Compared to the Zacks Consensus Estimate of $20.95 million, the reported revenues represent a surprise of +22.74%. The EPS surprise was +700%.Over the last four quarters, DecisionPoint Systems Inc. surpassed consensus EPS estimates three times. The company topped consensus revenue estimates three times over this period.ValuationNo investment decision can be efficient without considering a stock's valuation. Whether a stock's current price rightly reflects the intrinsic value of the underlying business and the company's growth prospects is an essential determinant of its future price performance.Comparing the current value of a company's valuation multiples, such as its price-to-earnings (P/E), price-to-sales (P/S), and price-to-cash flow (P/CF), to its own historical values helps ascertain whether its stock is fairly valued, overvalued, or undervalued, whereas comparing the company relative to its peers on these parameters gives a good sense of how reasonable its stock price is.As part of the Zacks Style Scores system, the Zacks Value Style Score (which evaluates both traditional and unconventional valuation metrics) organizes stocks into five groups ranging from A to F (A is better than B; B is better than C; and so on), making it helpful in identifying whether a stock is overvalued, rightly valued, or temporarily undervalued.DecisionPoint Systems Inc. is graded A on this front, indicating that it is trading at a discount to its peers. Click here to see the values of some of the valuation metrics that have driven this grade.Bottom LineThe facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about DecisionPoint Systems Inc. However, its Zacks Rank #2 does suggest that it may outperform the broader market in the near term. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report DecisionPoint Systems Inc. (DPSI): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research.....»»

Category: topSource: zacksFeb 2nd, 2023

Lumen (LUMN) Q4 Earnings Coming Up: Here"s What to Expect

Lumen's (LUMN) Q4 performance is likely to have been affected by supply-chain troubles, inflation and macroeconomic weakness. Lumen Technologies, Inc LUMN is scheduled to report fourth-quarter 2022 results on Feb 7, after the closing bell.The Zacks Consensus Estimate for total revenues is pegged at $3.74 billion, suggesting a fall of 22.9% from the year-ago quarter’s reported figure. The Zacks Consensus Estimate for earnings is currently pegged at 13 cents per share, indicating a 74.5% decline from the year-ago quarter’s levels. Our projection for the top and bottom line is $3.585 billion and 4 cents per share, respectively.The company missed the Zacks Consensus Estimate in three of the last four quarters and beat once. It has a trailing four-quarter negative earnings surprise of 13.83%, on average.In the last reported quarter, Lumen, an LA-based telecommunications company, delivered adjusted earnings (excluding special items) of 14 cents per share compared with 49 cents per share in the prior-year quarter. The bottom line missed the Zacks Consensus Estimate by 61.1%.Lumen Technologies, Inc. Price and EPS Surprise Lumen Technologies, Inc. price-eps-surprise | Lumen Technologies, Inc. QuoteQuarterly total revenues dropped 10.2% year over year to $4,390 million. On a pro forma basis, quarterly total revenues declined 6% year over year to $4,328 million.In the past year, shares of the company have lost 57.5% compared with the sub-industry’s decline of 27.3%Image Source: Zacks Investment ResearchFactors at PlayWeakness in mid-market demand, a decline in legacy voice services and substitution of its traditional wireline telephone services by wireless and other competitive low-priced offerings, together with massive debt are concerns. The company is undergoing a time-consuming digital transformation process.Supply-chain woes, uncertainty prevailing over global macroeconomic conditions, forex volatility and inflationary pressure are likely to have affected Lumen’s fourth-quarter revenues. Conclusion of CAF II program is likely to result in tougher year-over-year comparisons.However, momentum in security, cloud, unified communications and IT products is likely to have offered some cushioning to the top-line performance.Further, continued investments in Quantum Fiber and enterprise business bode well. In the last reported quarter, Lumen added 31,000 quantum fiber subscribers, taking the count to 889,000 quantum fiber subscribers at the end of the reported quarter. Total “enablements” were nearly 210,000, with 195,000 of these enabled locations in the company’s 16 retained states. As of Sep 30, 2022, the total enabled locations in the retained states stood at 3 million.Earnings WhispersOur proven model does not conclusively predict an earnings beat for Lumen this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.Lumen has an Earnings ESP of -24.00% and a Zacks Rank #4 (Sell).  You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.Stocks to ConsiderHere are a few stocks that you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.Onto Innovation ONTO has an Earnings ESP of +4.22% and presently carries a Zacks Rank #3. The company is slated to release quarterly numbers on Feb 9. You can see the complete list of today’s Zacks #1 Rank stocks here.The Zacks Consensus Estimate for Onto Innovation’s to-be-reported quarter’s earnings and revenues are pegged at $1.34 per share and $255 million, respectively. Shares of ONTO have lost 10.3% in the past year.Perion Network PERI has an Earnings ESP of +13.4% and presently carries a Zacks Rank #3. The company is slated to release quarterly numbers on Feb 8.The Zacks Consensus Estimate for Perion Network’s to-be-reported quarter’s earnings and revenues are pegged at 70 cents per share and $205.1 million, respectively. Shares of PERI have gained 60.1% in the past year.Take-Two Interactive Software TTWO has an Earnings ESP of +3.54% and presently carries a Zacks Rank #3. The company is slated to release quarterly numbers on Feb 6.The Zacks Consensus Estimate for TTWO’s to-be-reported quarter’s earnings and revenues are pegged at 88 cents per share and $1.44 billion, respectively. Shares of the company have lost 32% of their value in the past year.Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Take-Two Interactive Software, Inc. (TTWO): Free Stock Analysis Report Perion Network Ltd (PERI): Free Stock Analysis Report Onto Innovation Inc. (ONTO): Free Stock Analysis Report Lumen Technologies, Inc. (LUMN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research.....»»

Category: topSource: zacksFeb 2nd, 2023

Prestige Consumer Healthcare Inc. Reports Third Quarter Results

Revenue of $275.5 Million in Q3 fiscal 2023 increased 0.4% versus Prior Year and 1.8% excluding Currency Diluted EPS of $1.04 for Q3 fiscal 2023 increased 5.1% versus Prior Year Reduced leverage ratio to 3.5x in Q3, enabled by strong profitability and cash flow TARRYTOWN, N.Y., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its third fiscal quarter ended December 31, 2022. "In Q3 our business continued to generate solid revenue and earnings growth in a dynamic consumer and retail environment driven by our diversified portfolio of brands and proven business model.   Our continued strong sales and profit growth drives our cash flow that continued to reduce our leverage ratio during the quarter and has us well positioned as we finish our fiscal year," said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare. Third Fiscal Quarter Ended December 31, 2022Reported revenues in the third quarter of fiscal 2023 of $275.5 million increased 0.4% from $274.5 million in the third quarter of fiscal 2022. Revenues increased 1.8% excluding the impact of foreign currency. The revenue growth for the quarter was led by strong performance in our International OTC segment and strong Cough & Cold category sales versus the prior year comparable period. Reported net income for the third quarter of fiscal 2023 totaled $52.0 million, compared to the prior year third quarter's net income of $50.2 million. Diluted earnings per share of $1.04 for the third quarter of fiscal 2023 compared to diluted earnings per share of $0.99 in the prior year comparable period. Nine Months Ended December 31, 2022Reported revenues for the first nine months of fiscal 2023 totaled $841.9 million, an increase of 2.7%, compared to revenues of $819.9 million for the first nine months of fiscal 2022. Revenues increased 2.0% excluding the impact of foreign currency and a $12.6 million contribution from the acquisition of Akorn in Q1 fiscal 2023. The revenue growth for the first nine months was driven by strong International OTC segment performance and improved demand for certain brands, categories and channels that had been impacted by the COVID-19 virus in the first nine months of the prior fiscal year. Reported net income for the first nine months of fiscal 2023 totaled $158.2 million versus the prior year comparable period net income and adjusted net income of $153.3 million and $160.0 million, respectively. Diluted earnings per share were $3.14 for the first nine months of fiscal 2023 compared to diluted earnings per share and adjusted earnings per share of $3.02 and $3.15 in the prior year comparable period, respectively. Adjustments to net income in the first nine months of fiscal 2022 included integration, transition, purchase accounting, legal and various other costs associated with the Akorn acquisition, as well as a loss on extinguishment of debt and the related income tax effects of the adjustments. Free Cash Flow and Balance SheetThe Company's net cash provided by operating activities for third quarter fiscal 2023 was $54.9 million, compared to $66.3 million during the prior year comparable period. Non-GAAP free cash flow in the third quarter of fiscal 2023 was $53.1 million, a decrease compared to $64.1 million in the prior year comparable period. The Company's net cash provided by operating activities for the first nine months of fiscal 2023 was $170.7 million, compared to $196.8 million during the prior year comparable period. Non-GAAP free cash flow in the first nine months of fiscal 2023 was $165.5 million compared to $193.8 million in the prior year comparable period. The change in free cash flow for the nine months is largely due to an increase in working capital as the Company has focused on increasing inventory to improve service levels. The Company's net debt position as of December 31, 2022 was approximately $1.4 billion, resulting in a covenant-defined leverage ratio of 3.5x. Segment ReviewNorth American OTC Healthcare: Segment revenues of $236.9 million for the third quarter fiscal 2023 compared to the prior year comparable quarter's segment revenues of $240.9 million. The revenue performance for the quarter was driven by strong performance across many of our key brands, particularly in the Cough & Cold and Gastrointestinal categories but was offset by lower Women's Health and Eye & Ear Care category sales compared to the prior year comparable period. For the first nine months of the current fiscal year, reported revenues for the North American OTC segment were $731.5 million compared to $735.0 million in the prior year comparable period. The change was driven by increased demand for certain brands, categories and channels that had previously been impacted by the COVID-19 virus, most notably Cough & Cold and motion sickness products and an approximate $12.4 million contribution from the acquisition of Akorn in the first quarter fiscal 2023, but more than offset by lower Women's Health category sales. International OTC Healthcare: Record segment fiscal third quarter 2023 revenues of $38.6 million increased 15.0% from $33.6 million reported in the prior year comparable period. The revenue increase versus the prior year third quarter was driven by increased consumer demand across the segment's key brands, partially offset by a $2.8 million currency headwind. For the first nine months of the current fiscal year, reported revenues for the International OTC Healthcare segment were $110.4 million, an increase of 30.0% over the prior year comparable period's revenues of $84.9 million. The increase compared to the prior year was driven by large increases in the segment's Australia business led by the Hydralyte brand, partially offset by a foreign currency headwind of $5.3 million. Commentary and Updated Outlook for Fiscal 2023Ron Lombardi, Chief Executive Officer, stated, "Our third quarter marked another period of successful execution against our long-term three-pillar strategy, with solid top-line revenue organic growth of approximately 2% and mid-single-digit earnings growth. The strong sales performance was driven by strength in our international segment and the Cough & Cold category and resulted in cash flow generation that enabled us to continue investing in our business while reducing our leverage to the lowest level in over 10 years. These investments included increasing our inventory levels during the quarter in order to improve service levels to our customers and positions us for continued growth in fiscal 2024." "With one quarter to go in fiscal year 2023 we anticipate sales between $1,120 and $1,122 equating to over 3% growth on top of our record fiscal 2022 results. Looking ahead, our proven business strategy, portfolio positioning, and improvements in our service levels have us well positioned for further revenue, earnings, and free cash flow growth in fiscal 2024," Mr. Lombardi concluded.   Updated Fiscal 2023 Outlook Revenue $1,120 to 1,122 million Organic Revenue Growth Approximately 3% Diluted E.P.S. Approximately $4.18 Free Cash Flow Approximately $220 million Fiscal Third Quarter 2023 Conference Call, Accompanying Slide Presentation and ReplayThe Company will host a conference call to review its third quarter results today, February 2, 2023 at 8:30 a.m. ET. The Company provides a live Internet webcast, a slide presentation to accompany the call, as well as an archived replay, all of which can be accessed from the Investor Relations page of the Company's website at www.prestigeconsumerhealthcare.com. To participate in the conference call via phone, participants may register for the call here to receive dial-in details and a unique pin. While not required, it is recommended to join 10 minutes prior to the event start.   The slide presentation can be accessed from the Investor Relations page of the website by clicking on Webcasts and Presentations. A conference call replay will be available for approximately one week following completion of the live call and can be accessed on the Company's Investor Relations page. Non-GAAP and Other Financial InformationIn addition to financial results reported in accordance with generally accepted accounting principles (GAAP), we have provided certain non-GAAP financial information in this release to aid investors in understanding the Company's performance.   Each non-GAAP financial measure is defined and reconciled to its most closely related GAAP financial measure in the "About Non-GAAP Financial Measures" section at the end of this earnings release. Note Regarding Forward-Looking Statements This news release contains "forward-looking statements" within the meaning of the federal securities laws that are intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995.   "Forward-looking statements" generally can be identified by the use of forward-looking terminology such as "guidance," "outlook," "looking ahead," "projection," "plan," "positioned," "may," "will," "would," "expect," "anticipate," "believe", "consistent," or "continue" (or the negative or other derivatives of each of these terms) or similar terminology.   The "forward-looking statements" include, without limitation, statements regarding the Company's future operating results including revenues, organic growth, diluted earnings per share, and free cash flow, the impact of changes in the Company's inventory on customer service levels, the Company's ability to grow. These statements are based on management's estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict.   Actual results could differ materially from those expected as a result of a variety of factors, including the impact of business and economic conditions, including as a result of COVID-19 and geopolitical instability, consumer trends, the impact of the Company's advertising and marketing and new product development initiatives, customer inventory management initiatives, fluctuating foreign exchange rates, competitive pressures, and the ability of the Company's manufacturing operations and third party manufacturers and logistics providers and suppliers to meet demand for its products and to avoid inflationary cost increases and disruption as a result of labor shortages. A discussion of other factors that could cause results to vary is included in the Company's Annual Report on Form 10-K for the year ended March 31, 2022 and other periodic reports filed with the Securities and Exchange Commission. About Prestige Consumer Healthcare Inc.Prestige Consumer Healthcare is a leading consumer healthcare products company with sales throughout the U.S. and Canada, Australia, and in certain other international markets. The Company's diverse portfolio of brands include Monistat® and Summer's Eve® women's health products, BC® and Goody's® pain relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products, Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric over-the-counter products, Boudreaux's Butt Paste® diaper rash ointments, Nix® lice treatment, Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com. Prestige Consumer Healthcare Inc.Condensed Consolidated Statements of Income and Comprehensive Income (Unaudited)     Three Months EndedDecember 31,   Nine Months EndedDecember 31, (In thousands, except per share data)     2022     2021     2022       2021   Total Revenues   $ 275,524   $ 274,470   $ 841,856     $ 819,876                     Cost of Sales                 Cost of sales excluding depreciation     123,251     117,604     364,631       342,661   Cost of sales depreciation     1,871     1,806     5,695       5,431   Cost of sales     125,122     119,410     370,326       348,092   Gross profit     150,402     155,060     471,530       471,784                     Operating Expenses                 Advertising and marketing     30,423     40,239     114,193       120,408   General and administrative     26,536     25,983     79,688       80,706   Depreciation and amortization     6,259     6,244     19,067       18,176   Total operating expenses     63,218     72,466     212,948       219,290   Operating income     87,184     82,594     258,582       252,494                     Other expense                 Interest expense, net     17,917     16,924     50,188       48,314   Loss on extinguishment of debt     —     —     —       2,122   Other expense, net     1,150     177     2,787       565   Total other expense, net     19,067     17,101     52,975       51,001   Income before income taxes     68,117     65,493     205,607       201,493   Provision for income taxes     16,166     15,278     47,361       48,198   Net income   $ 51,951   $ 50,215   $ 158,246     $ 153,295                     Earnings per share:                 Basic   $ 1.05   $ 1.00   $ 3.17     $ 3.05   Diluted   $ 1.04   $ 0.99   $ 3.14     $ 3.02                     Weighted average shares outstanding:                 Basic     49,693     50,303     49,919       50,225   Diluted     50,186     50,935     50,392       50,799                     Comprehensive income, net of tax:                 Currency translation adjustments     6,970     652     (9,667 )     (5,037 ) Unrealized gain on interest rate swaps     —     561     —       1,631   Net loss on termination of pension plan     —     —     (790 )     —   Total other comprehensive income (loss)     6,970     1,213     (10,457 )     (3,406 ) Comprehensive income   $ 58,921   $ 51,428   $ 147,789     $ 149,889   Prestige Consumer Healthcare Inc.Condensed Consolidated Balance Sheets(Unaudited) (In thousands) December 31,2022   March 31,2022         Assets       Current assets       Cash and cash equivalents $ 86,358     $ 27,185   Accounts receivable, net of allowance of $21,370 and $19,720, respectively   157,081       139,330   Inventories   158,522       120,342   Prepaid expenses and other current assets   6,886       6,410   Total current assets   408,847       293,267           Property, plant and equipment, net   69,569       71,300   Operating lease right-of-use assets   16,410       20,372   Finance lease right-of-use assets, net   4,864       6,858   Goodwill   576,602       578,976   Intangible assets, net   2,670,328       2,696,635   Other long-term assets   3,154       3,273   Total Assets $ 3,749,774     $ 3,670,681           Liabilities and Stockholders' Equity       Current liabilities       Accounts payable   64,254       55,760   Accrued interest payable   15,267       4,437   Operating lease liabilities, current portion   6,858       6,360   Finance lease liabilities, current portion   2,814       2,752   Other accrued liabilities   70,983       74,113   Total current liabilities   160,176       143,422           Long-term debt, net   1,424,095       1,476,658   Deferred income tax liabilities   455,826       444,917   Long-term operating lease liabilities, net of current portion   11,559       16,088   Long-term finance lease liabilities, net of current portion   2,383       4,501   Other long-term liabilities   8,872       7,484   Total Liabilities   2,062,911       2,093,070           Total Stockholders' Equity   1,686,863       1,577,611   Total Liabilities and Stockholders' Equity $ 3,749,774     $ 3,670,681   Prestige Consumer Healthcare Inc.Condensed Consolidated Statements of Cash Flows(Unaudited)   Nine Months Ended December 31, (In thousands)  .....»»

Category: earningsSource: benzingaFeb 2nd, 2023

HONEYWELL DELIVERS STRONG FOURTH QUARTER RESULTS, FULL YEAR SEGMENT MARGIN AND EARNINGS ABOVE HIGH END OF INITIAL GUIDANCE DESPITE SIGNIFICANT HEADWINDS; ISSUES 2023 GUIDANCE

Fourth Quarter Sales of $9.2 Billion, Reported Sales Up 6%, Organic1 Sales Up 10% Fourth Quarter Earnings Per Share of $1.51 and Adjusted Earnings Per Share1 of $2.52, Above Midpoint of Previous Guidance Full Year Operating Cash Flow of $5.3 Billion and Free Cash Flow1 of $4.9 Billion, at Midpoint of Previous Guidance Deployed $7.9 Billion of Capital to Share Repurchases, Dividends, Capital Expenditures, and M&A in 2022, Exceeded Commitment of $4.0 Billion in Share Repurchases Expect 2023 Adjusted Earnings Per Share of $8.80 - $9.20, Up 0% - 5% Adjusted2,3, or Up 7% - 11% Excluding Pension Headwind CHARLOTTE, N.C., Feb. 2, 2023 /PRNewswire/ -- Honeywell (NASDAQ:HON) today announced results for the fourth quarter and full year 2022 that met or exceeded the company's original guidance despite a challenging operating environment. The company also provided its outlook for 2023. The company reported fourth-quarter year-over-year sales growth of 6% and organic1 sales growth of 10%, or 11% excluding the impact of the wind down in operations in Russia4, with another quarter of double-digit organic sales growth in Honeywell Building Technologies, Performance Materials and Technologies, and Aerospace. Demand remained strong, with closing backlog5 of $29.6 billion, up 7% year over year. Fourth-quarter operating margin expanded 220 basis points to 19.7%, or 240 basis points excluding the year-over-year impact of Quantinuum. Segment margin1 expanded 150 basis points to 22.9%, or 180 basis points excluding the year-over-year impact of Quantinuum1, led by another strong quarter of margin expansion in Safety and Productivity Solutions and Honeywell Building Technologies. Honeywell delivered fourth-quarter earnings per share of $1.51, down 26% year over year, and adjusted earnings per share1 of $2.52, up 21% year over year. Operating cash flow was $2.4 billion with operating cash flow margin of 25.8%, and free cash flow1 was $2.1 billion with free cash flow margin1 of 23.1%, driven by strong net income and reduced working capital quarter over quarter. For the full year, sales increased by 3%, or 6% on an organic1 basis, and operating margin expanded 10 basis points, with segment margin1 expanding 70 basis points. Honeywell reported full-year earnings per share of $7.27 and adjusted earnings per share1 of $8.76, above the high end of the company's initial guidance of $8.40 - $8.70. "Honeywell delivered a strong finish to another challenging year, meeting our original guidance for the year despite significant headwinds from FX and the wind down of our operations in Russia," said Darius Adamczyk, chairman and chief executive officer of Honeywell. "We also met our latest guidance for all metrics in the fourth quarter. Organic1 sales growth of 10% in the quarter was underpinned by double-digit growth in our commercial aviation, building products, advanced materials, and UOP businesses. Our disciplined cost management enabled us to expand segment margin1 by 150 basis points, led by 940 basis points of margin expansion in Safety and Productivity Solutions to 20.2%, the highest ever segment margin for that business. Our strong balance sheet allowed us to execute on our capital deployment strategy once again, deploying $2.3 billion in the quarter, including $1.4 billion in share repurchases to fulfill our 2022 share repurchase commitment from our March Investor Day." Adamczyk continued, "As we have consistently shown over the past three years, Honeywell's operating principles enable us to outperform in any macroeconomic environment. As we look toward 2023, we are well-positioned to remain resilient and deliver differentiated results. Our backlog remains at a record level, ending 2022 at $29.6 billion, and will help support growth throughout the year. Late-cycle aerospace and energy end markets are positioned for a strong growth year in 2023, we are demonstrating commercial progress in digital offerings through our Forge platform, and we remain focused on growing our sustainability initiatives such as renewable fuels, carbon capture, and sustainable buildings. I am confident that 2023 will be another strong performance for our shareowners, our customers, and our employees." Honeywell also announced its outlook for 2023. The company expects sales of $36.0 billion to $37.0 billion, representing year-over-year organic growth of 2% to 5%; segment margin expansion2 of 50 to 90 basis points; adjusted earnings per share2 of $8.80 to $9.20, flat to up 5% despite an approximately $0.55 non-cash pension headwind; operating cash flow of $4.9 billion to $5.3 billion, and free cash flow1 of $3.9 billion to $4.3 billion, or $5.1 billion to $5.5 billion excluding the net impact of settlements signed in the fourth quarter of 2022. A summary of the company's 2023 guidance can be found in Table 1. Fourth-Quarter Performance Honeywell sales for the fourth quarter were up 6% year over year on a reported basis and 10% year over year on an organic basis1. The fourth-quarter financial results can be found in Tables 2 and 3. Aerospace sales for the fourth quarter were up 11% year over year on an organic basis1 led by commercial aviation. Sales growth was the strongest in commercial original equipment, increasing 25% organically year over year on increased shipset deliveries, especially to business and general aviation customers. Commercial aftermarket sales also grew over 20% organically year over year as flight hours continue on their recovery path to pre-COVID levels. Air transport aftermarket was particularly strong, growing 25% organically in the quarter. Increased commercial aviation sales were partially offset by lower defense volumes year over year, although defense and space sales increased 15% sequentially in the fourth quarter. Segment margin contracted 120 basis points to 27.8% driven by increased sales of lower margin original equipment products, partially offset by commercial excellence. Honeywell Building Technologies sales for the fourth quarter were up 15% on an organic basis1 year over year with strength in both building products and building solutions. Building products sales increased 21% organically, primarily driven by increased sales of fire products and building management systems. Project sales grew double digits organically for the third consecutive quarter, leading the growth in building solutions. Segment margin expanded 370 basis points to 24.8% due to commercial excellence, partially offset by cost inflation. Performance Materials and Technologies sales for the fourth quarter were up 15% on an organic basis1 year over year despite an approximately 4% headwind from Russia. Sales growth was led by more than 30% organic growth in fluorine products within advanced materials and refining catalyst shipments in UOP, as well as double-digit organic growth in thermal solutions and lifecycle solutions and services within process solutions. Segment margin contracted 100 basis points to 22.0%, primarily driven by cost inflation and higher sales of lower margin products, partially offset by commercial excellence. Safety and Productivity Solutions sales for the fourth quarter decreased 5% on an organic basis1 year over year. Growth in sensing and safety technologies was offset by lower volumes in productivity solutions and services and warehouse and workflow solutions. Segment margin grew at the fastest rate ever for SPS, expanding 940 basis points to 20.2% as a result of commercial excellence, improved sales mix, and productivity actions, partially offset by volume leverage and cost inflation. Conference Call Details Honeywell will discuss its fourth-quarter results and full-year 2023 guidance during an investor conference call starting at 8:30 a.m. Eastern Standard Time today. A live webcast of the investor call as well as related presentation materials will be available through the Investor Relations section of the company's website (www.honeywell.com/investor). A replay of the webcast will be available for 30 days following the presentation.  TABLE 1: FULL-YEAR 2023 GUIDANCE2  Sales $36.0B - $37.0B Organic Growth 2% - 5% Segment Margin 22.2% - 22.6% Expansion Up 50 - 90 bps Adjusted Earnings Per Share3 $8.80 - $9.20 Adjusted Earnings Growth3 0% - 5% Adjusted Earnings Per Share Excluding Pension Headwind $9.35 - $9.75 Adjusted Earnings Growth Excluding Pension Headwind 7% - 11% Operating Cash Flow $4.9B - $5.3B Free Cash Flow $3.9B - $4.3B Free Cash Flow Excluding Impact of Settlements $5.1B - $5.5B   TABLE 2: SUMMARY OF HONEYWELL FINANCIAL RESULTS FY 2022 FY 2021 Change Sales 35,466 34,392 3 % Organic Growth1 6 % Operating Income Margin 18.1 % 18.0 % 10 bps Segment Margin1 21.7 % 21.0 % 70 bps Reported Earnings Per Share $7.27 $7.91 (8) % Adjusted Earnings Per Share1 $8.76 $8.06 9 % Cash Flow from Operations 5,274 6,038 (13) % Operating Cash Flow Margin 14.9 % 17.6 % (270) bps Free Cash Flow1 4,917 5,729 (14) % Free Cash Flow Margin1 13.9 % 16.7 % (280) bps 4Q 2022 4Q 2021 Change Sales 9,186 8,657 6 % Organic Growth1 10 % Operating Income Margin 19.7 % 17.5 % 220 bps Segment Margin1 22.9 % 21.4 % 150 bps Reported Earnings Per Share $1.51 $2.05 (26) % Adjusted Earnings Per Share1 $2.52 $2.09 21 % Cash Flow from Operations 2,366 2,663 (11) % Operating Cash Flow Margin 25.8 % 30.8 % (500) bps Free Cash Flow1 2,125 2,593 (18) % Free Cash Flow Margin 23.1 % 30.0 % (690) bps   TABLE 3: SUMMARY OF SEGMENT FINANCIAL RESULTS AEROSPACE FY 2022 FY 2021 Change Sales 11,827 11,026 7 % Organic Growth1 8 % Segment Profit 3,228 3,051 6 % Segment Margin 27.3 % 27.7 % -40 bps 4Q 2022 4Q 2021 Sales 3,204 2,896 11 % Organic Growth1 11 % Segment Profit 890 839 6 % Segment Margin 27.8 % 29.0 % -120 bps HONEYWELL BUILDING TECHNOLOGIES FY 2022 FY 2021 Change Sales 6,000 5,539 8 % Organic Growth1 14 % Segment Profit 1,439 1,238 16 % Segment Margin 24.0 % 22.4 % 160 bps 4Q 2022 4Q 2021 Sales 1,514 1,404 8 % Organic Growth1 15 % Segment Profit 375 296 27 % Segment Margin 24.8 % 21.1 % 370 bps PERFORMANCE MATERIALS AND TECHNOLOGIES FY 2022 FY 2021 Change Sales 10,727 10,013 7 % Organic Growth1 11 % Segment Profit 2,354 2,120 11 % Segment Margin 21.9 % 21.2 % 70 bps 4Q 2022 4Q 2021 Sales 2,860 2,605 10 % Organic Growth1 15 % Segment Profit 628 598 5 % Segment Margin 22.0 % 23.0 % -100 bps SAFETY AND PRODUCTIVITY SOLUTIONS FY 2022 FY 2021 Change Sales 6,907 7,814 (12) % Organic Growth1 (9) % Segment Profit 1,080 1,029 5 % Segment Margin 15.6 % 13.2 % 240 bps 4Q 2022 4Q 2021 Sales 1,607 1,752 (8) % Organic Growth1 (5) % Segment Profit 325 189 72 % Segment Margin 20.2 % 10.8 % 940 bps 1See additional information at the end of this release regarding non-GAAP financial measures. 2Segment margin and adjusted EPS are non-GAAP financial measures. Management cannot reliably predict or estimate, without unreasonable effort, the impact and timing on future operating results arising from items excluded from segment margin or adjusted EPS. We therefore, do not present a guidance range, or a reconciliation to, the nearest GAAP financial measures of operating margin or EPS. 3Adjusted EPS and adjusted EPS V% guidance excludes items identified in the non-GAAP reconciliation of adjusted EPS at the end of this release, and any potential future one-time items that we cannot reliably predict or estimate such as pension mark-to-market. 4Lost Russian sales is defined as the year-over-year decline in sales due to the decision to wind down our businesses and operations in Russia. This does not reflect management's estimate of 2022 Russian sales absent the decision to wind down our businesses and operations in Russia. 5Effective March 31, 2022, performance obligations exclude contracts with customers related to Russia as collectability is not reasonably assured. Backlog V% includes prior year revisions to reflect a prior period correction, which had no impact on our results of operations.   Honeywell (www.honeywell.com) delivers industry specific solutions that include aerospace products and services; control technologies for buildings and industry; and performance materials globally. Our technologies help everything from aircraft, buildings, manufacturing plants, supply chains, and workers become more connected to make our world smarter, safer, and more sustainable. For more news and information on Honeywell, please visit www.honeywell.com/newsroom. Honeywell uses our Investor Relations website, www.honeywell.com/investor, as a means of disclosing information which may be of interest or material to our investors and for complying with disclosure obligations under Regulation FD. Accordingly, investors should monitor our Investor Relations website, in addition to following our press releases, SEC filings, public conference calls, webcasts, and social media. This release contains certain statements that may be deemed "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are those that address activities, events or developments that management intends, expects, projects, believes or anticipates will or may occur in the future. They are based on management's assumptions and assessments in light of past experience and trends, current economic and industry conditions, expected future developments and other relevant factors. They are not guarantees of future performance, and actual results, developments and business decisions may differ significantly from those envisaged by our forward-looking statements. We do not undertake to update or revise any of our forward-looking statements, except as required by applicable securities law. Our forward-looking statements are also subject to risks and uncertainties, including the impact of the COVID-19 pandemic and the Russia-Ukraine conflict, that can affect our performance in both the near- and long-term. In addition, no assurance can be given that any plan, initiative, projection, goal commitment, expectation, or prospect set forth in this release can or will be achieved. Any forward-looking plans described herein are not final and may be modified or abandoned at any time. We identify the principal risks and uncertainties that affect our performance in our Form 10-K and other filings with the Securities and Exchange Commission. This release contains financial measures presented on a non-GAAP basis. Honeywell's non-GAAP financial measures used in this release are as follows: Segment profit, on an overall Honeywell basis; Segment profit, excluding Quantinuum; Segment profit margin, on an overall Honeywell basis; Segment margin excluding Quantinuum; Expansion in segment profit margin percentage; Expansion in segment profit margin percentage excluding Quantinuum; Organic sales growth; Organic sales growth excluding lost Russian sales; Free cash flow; Free cash flow excluding impact of settlements; Free cash flow margin; Adjusted earnings per share; and Adjusted earnings per share excluding pension headwind. Management believes that, when considered together with reported amounts, these measures are useful to investors and management in understanding our ongoing operations and in the analysis of ongoing operating trends. These measures should be considered in addition to, and not as replacements for, the most comparable GAAP measure. Certain measures presented on a non-GAAP basis represent the impact of adjusting items net of tax. The tax-effect for adjusting items is determined individually and on a case-by-case basis. Refer to the Appendix attached to this release for reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures.   Honeywell International Inc.Consolidated Statement of Operations(Unaudited)(Dollars in millions, except per share amounts) Three Months Ended December 31, Twelve Months Ended December 31, 2022 2021 2022 2021 Product sales $            6,556 $            6,362 $          25,960 $          25,643 Service sales 2,630 2,295 9,506 8,749 Net sales 9,186 8,657 35,466 34,392 Costs, expenses and other Cost of products sold (1) 4,587 4,596 18,263 18,344 Cost of services sold (1) 1,537 1,340 5,562 5,050 6,124 5,936 23,825 23,394 Selling, general and administrative expenses (1) 1,249 1,203 5,214 4,798 Other (income) expense 480 (355) (366) (1,378) Interest and other financial charges 144 80 414 343 7,997.....»»

Category: earningsSource: benzingaFeb 2nd, 2023

Dow Jones Newswires: Sony profit falls as movie business earnings weaken and cuts revenue forecast

Sony cut its revenue forecast for the fiscal year ending in March, but raised its net-profit projection and increased its operating-profit forecast for its gaming business......»»

Category: topSource: marketwatchFeb 2nd, 2023

Barings BDC (BBDC) Flat As Market Gains: What You Should Know

In the latest trading session, Barings BDC (BBDC) closed at $8.76, marking no change from the previous day. Barings BDC (BBDC) closed the most recent trading day at $8.76, making no change from the previous trading session. This change lagged the S&P 500's 1.05% gain on the day. Elsewhere, the Dow gained 0.02%, while the tech-heavy Nasdaq added 9.7%.Prior to today's trading, shares of the business development company had gained 6.57% over the past month. This has lagged the Finance sector's gain of 7.81% and outpaced the S&P 500's gain of 6.27% in that time.Barings BDC will be looking to display strength as it nears its next earnings release, which is expected to be February 23, 2023. On that day, Barings BDC is projected to report earnings of $0.27 per share, which would represent year-over-year growth of 17.39%. Meanwhile, our latest consensus estimate is calling for revenue of $62.47 million, up 70.65% from the prior-year quarter.It is also important to note the recent changes to analyst estimates for Barings BDC. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Barings BDC is currently a Zacks Rank #3 (Hold).In terms of valuation, Barings BDC is currently trading at a Forward P/E ratio of 7.87. Its industry sports an average Forward P/E of 8.1, so we one might conclude that Barings BDC is trading at a discount comparatively.The Financial - SBIC & Commercial Industry industry is part of the Finance sector. This group has a Zacks Industry Rank of 66, putting it in the top 27% of all 250+ industries.The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.You can find more information on all of these metrics, and much more, on Zacks.com. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BARINGS BDC, INC. (BBDC): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research.....»»

Category: topSource: zacksFeb 1st, 2023

Constellation Energy Corporation (CEG) Gains But Lags Market: What You Should Know

In the latest trading session, Constellation Energy Corporation (CEG) closed at $85.41, marking a +0.06% move from the previous day. In the latest trading session, Constellation Energy Corporation (CEG) closed at $85.41, marking a +0.06% move from the previous day. This move lagged the S&P 500's daily gain of 1.05%. Elsewhere, the Dow gained 0.02%, while the tech-heavy Nasdaq added 9.7%.Prior to today's trading, shares of the company had gained 4.21% over the past month. This has outpaced the Oils-Energy sector's gain of 3.04% and lagged the S&P 500's gain of 6.27% in that time.Constellation Energy Corporation will be looking to display strength as it nears its next earnings release, which is expected to be February 16, 2023.Investors should also note any recent changes to analyst estimates for Constellation Energy Corporation. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 2.95% lower. Constellation Energy Corporation is currently sporting a Zacks Rank of #3 (Hold).Valuation is also important, so investors should note that Constellation Energy Corporation has a Forward P/E ratio of 18.54 right now. This represents a discount compared to its industry's average Forward P/E of 25.17.We can also see that CEG currently has a PEG ratio of 0.51. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. CEG's industry had an average PEG ratio of 2.27 as of yesterday's close.The Alternative Energy - Other industry is part of the Oils-Energy sector. This industry currently has a Zacks Industry Rank of 179, which puts it in the bottom 29% of all 250+ industries.The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. Zacks Names "Single Best Pick to Double" From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all. It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time. This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.Free: See Our Top Stock and 4 Runners Up >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Constellation Energy Corporation (CEG): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research.....»»

Category: topSource: zacksFeb 1st, 2023